<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B2555E26-9A3A-4509-913E-4FAB56AD6509"><gtr:id>B2555E26-9A3A-4509-913E-4FAB56AD6509</gtr:id><gtr:firstName>Paolo</gtr:firstName><gtr:surname>Gallipoli</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000288"><gtr:id>AFBB7320-35D9-4955-BEFD-0F9B25B37123</gtr:id><gtr:title>The relevance of autocrine growth factor activation to the survival and proliferation of primitive CML cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000288</gtr:grantReference><gtr:abstractText>Chronic myeloid leukaemia (CML) is a blood cancer which is effectively treated with current therapies. However treatment is not curative and a proportion of patients will eventually die from it. One of the mechanisms behind CML resistance to current therapies is the presence of a population of cells, called leukaemic stem cells (LSC), which are insensitive to the treatment and have the potential to cause disease relapse. Professor Holyoake?s group has an established reputation in studying the mechanisms of LSC resistance and in developing new approaches to kill them. In this project her group will investigate the role of small proteins called growth factors (GF) in LSC survival. Its aim is to clarify exactly the role of GF in LSC survival to try to target these small molecules in order to kill LSC more effectively. The research will be carried out on cells from CML patients but will not involve patients directly. However this project will hopefully help identifying new potentially curative treatment options for CML patients. It is also probable that some of the mechanisms underlying LSC survival in CML are present in other form of cancers. This research might therefore also help developing new treatments for other tumours.</gtr:abstractText><gtr:technicalSummary>Background: Chronic Myeloid Leukaemia (CML) arises in a haemopoietic stem cell (HSC) that acquires the t(9;22) translocation, resulting in the Philadelphia chromosome (Ph+). This creates the fusion gene and oncogenic tyrosine kinase (TK), BCR-ABL. Standard therapy with tyrosine kinase inhibitors (TKI) is highly effective, however unlikely to be curative. One explanation is the persistence of disease at the stem cell level. Laboratory observations have demonstrated that CML stem cells (CSC) (e.g. CD34+38-) are insensitive to induction of apoptosis by TKI, although these agents exhibit potent anti-proliferative effects. CSC are able to proliferate in the absence of exogenous growth factor (GF) via either autocrine production of GF and/or ligand-independent receptor activation. These mechanisms require the presence of BCR-ABL oncogene. However inhibition of TK activity of BCR-ABL may not suffice to inhibit the activation of GF signalling pathways. If this is true, inhibition of GF signalling pathways alone or in combination with TKI may represent an alternative therapeutic strategy. 
Aims &amp;amp; objectives: 
1) To establish cytokine ligand and receptor profiles for normal CD34+38- stem cells versus untreated CML stem cells versus CML stem cells in which BCR-ABL kinase activity has been suppressed 
2) To investigate signalling pathways downstream of BCR-ABL for components that remain activated upon complete inhibition of BCR-ABL kinase activity
3) To investigate combination therapies that include a TKI plus an inhibitor of autocrine signalling, based on findings from aims 1-2
Design &amp;amp; methodology: Primary cells from patients and controls will be sorted, using fluorescence activated cell sorting (FACS), into stem and progenitor populations. GF gene expression will be assessed by Taqman quantitative RT-PCR and protein expression/activity by flow cytometry and Luminex aiming to find GF preferentially expressed in CSC both in the presence and absence of TKI. Signalling pathways activated via these candidate GF will then be investigated using Cell Biosciences CB1000. Finally, we will evaluate the effect of interruption of candidate GF signalling cascades, in the presence and absence of TKI, in CSC via survival, proliferation and stem cell function assays. 
Scientific and medical opportunities: Elucidation of mechanisms of survival and proliferation of CSC, particularly in the presence of TKI, will identify new therapeutic targets to eradicate TKI-insensitive CSC. New compounds will be tested and promising candidates will be taken forward to further testing in vivo. Information on mechanisms underlying CSC survival will also prompt evaluation of similar mechanisms in other cancerous conditions.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>203583</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>Protemoic analysis of the combined effect of TKI and JAK inhibitor on CML stem cells</gtr:description><gtr:id>BC4BFF27-0FBC-4B1D-9CD8-43A09FEDDD9F</gtr:id><gtr:impact>Presentation to international meetings</gtr:impact><gtr:outcomeId>Uuaxobr3XJD-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution mainly</gtr:partnerContribution><gtr:piContribution>Access to samples
Intellectual contribution</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Recruitment of volunteers donating normal bone marrow for research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8DD1743C-B22C-4F90-A8C8-0FD38807DD74</gtr:id><gtr:impact>Several normal volunteers donated bone marrow after me advertising our research

We obtained valuable material for our research lab. From a personal point of view I had to organise the ethics for this and was a good opportunity to understand better these processes</gtr:impact><gtr:outcomeId>q45rBrmpfWW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory open days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B37380E0-259E-421A-86D9-74E40811ABAC</gtr:id><gtr:impact>Several (cannot recall exact number) members of the public attended our lab open day where briefly we touched on our research project and outputs obtained

This open day was welcome by patients and will be repeated on a regular basis</gtr:impact><gtr:outcomeId>ETQsb7o2F1q</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FCA43B0E-3E65-412C-9FB9-B3BB3E63593E</gtr:id><gtr:title>Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5&amp;nbsp;years follow-up.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_12564_24_24032404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D56D319B-7440-4A71-B50D-7C864AAF29CE</gtr:id><gtr:title>Hurdles toward a cure for CML: the CML stem cell.</gtr:title><gtr:parentPublicationTitle>Hematology/oncology clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0889-8588</gtr:issn><gtr:outcomeId>KHLyQ33Nd2K</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>903922FA-B67C-4E45-AD6A-0B7FF774A67E</gtr:id><gtr:title>Autocrine TNF-a production supports CML stem and progenitor cell survival and enhances their proliferation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_12564_24_24041577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>026F3139-9AB4-40EB-9CCF-3F8378265501</gtr:id><gtr:title>Glutaminolysis is a metabolic dependency in FLT3acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a993840c15cf6.68712269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1456B35A-43C8-48AD-B3A6-07D12B4DA2AB</gtr:id><gtr:title>Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2818ed3e00fce516b946caeaff33806"><gtr:id>b2818ed3e00fce516b946caeaff33806</gtr:id><gtr:otherNames>Scott MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn><gtr:outcomeId>585d4849f28301.23145995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF616C21-6428-485A-8A30-73CB52522E9D</gtr:id><gtr:title>CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e3d556fca61b5488524916951e3e9eb"><gtr:id>9e3d556fca61b5488524916951e3e9eb</gtr:id><gtr:otherNames>Tarafdar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>588b62e49251d5.07468800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6D52CCA-7C45-4E3C-ADCC-F7FA68F88DAC</gtr:id><gtr:title>Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>RCVxvsLb3Rn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>764395D5-A4D4-4680-BF7E-07D16E14C5CB</gtr:id><gtr:title>Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9dcac9014b753b41b120fcd89c559d2"><gtr:id>e9dcac9014b753b41b120fcd89c559d2</gtr:id><gtr:otherNames>Horton SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>5a99384149a340.03257230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F7DB074-067A-4D99-AD6B-C39AD71876C5</gtr:id><gtr:title>JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54746de6314157.55360324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0CBED1A-5DD3-42A5-98F3-3AFC6941E343</gtr:id><gtr:title>Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3ec6a4c11f8e7c3da8154516355ddc3"><gtr:id>a3ec6a4c11f8e7c3da8154516355ddc3</gtr:id><gtr:otherNames>Shah M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>pm_12564_24_22325915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF0F7A42-0DED-4A29-9877-3C3EA3D23DE3</gtr:id><gtr:title>Novel epigenetic therapies in hematological malignancies: Current status and beyond.</gtr:title><gtr:parentPublicationTitle>Seminars in cancer biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-579X</gtr:issn><gtr:outcomeId>5a9938417d34d2.06183993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D860C4E8-FB67-40EC-AD7C-B0E98FE5C3E6</gtr:id><gtr:title>High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and thrombolysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d4c26695a3f15af5c645d49dbaa0937"><gtr:id>2d4c26695a3f15af5c645d49dbaa0937</gtr:id><gtr:otherNames>Castelli R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0929-5305</gtr:issn><gtr:outcomeId>5a993841092349.85257154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C0AFCE-049A-43B9-8106-96F5D2F7041D</gtr:id><gtr:title>Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6738ffe8504874637d8ff442bad8580"><gtr:id>b6738ffe8504874637d8ff442bad8580</gtr:id><gtr:otherNames>Chen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_12564_24_23446755</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000288</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>